Global tocilizumab shortage intensifies after demand spikes to treat delta variant
Click Here to Manage Email Alerts
Demand for tocilizumab IV has outpaced the global supply, exacerbated by increased demand following the drug’s emergency use authorization for COVID-19 and the surge in delta variant cases, the American College of Rheumatology reported.
Although the ACR noted that it is actively involved with the FDA’s Center for Drug Evaluation and Research as they work with Genentech to remedy the shortfall of tocilizumab (Actemra), the manufacturer has stated that the global shortage is expected to last “for at least the next several weeks.”
“The dramatic emergence of the COVID-19 delta variant, as well as the unexpected slowing of vaccination rates in the U.S., has led to an overwhelmingly high incidence of COVID-19 hospitalizations in certain areas of the country,” Genentech said in a statement released Aug. 16. “This new wave of the pandemic has led to Genentech experiencing an unprecedented demand for Actemra IV — well over 400% of pre-COVID levels over the last 2 weeks alone and it continues to increase.”
Currently, Genentech has reported a “temporary stockout of Actemra IV in the U.S.” for both the 200 mg and 400 mg vials, as well as a dwindling supply of 80 mg vials that it expects to be out of stock within the next few days.
The ACR highlighted that “providers may currently find tocilizumab IV supplies to be unavailable due to high demand, but they expect IV stock replenishments by the end of August.” Additionally, although efforts are being made to expedite replenishments and increase manufacturing capacity and supply where possible, Genentech maintains that if the spread of COVID-19 continues at its current pace, “we anticipate additional periods of stockout in the weeks and months ahead.”
The ACR noted that Genentech has sustained a supply of subcutaneous tocilizumab that is indicated solely for patients with multiple inflammatory diseases, and not authorized for treatment of COVID-19 under the EUA. However, in light of surging demand for the drug and reduced availability elsewhere, “the supply situation continues to evolve,” according to Genentech.
The ACR has requested that any providers experiencing difficulty obtaining tocilizumab IV or any other issues related to COVID-19 to contact the association at COVID@rheumatology.org.
Click Here to Manage Email Alerts